loader
report-image

Uveitis Treatment Market Size, Industry Analysis Report By Treatment Type (Corticosteroids, Immunosuppressant, Monoclonal Antibodies, Cycloplegic Agents, Antibiotics, Antiviral, Antifungal, Analgesics), By Disease Type (Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis, Panuveitis), By Cause (Infectious and Non-infectious), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) & Region – Forecasts

  • PUBLISHED ON
  • 30/08/2022
  • NO OF PAGES
  • 258
  • CATEGORY
  • Healthcare & Life Sciences

Market Overview

The global Uveitis Treatment market was valued at USD 705.6 million in 2022 and expected to grow at a CAGR of 4.6% during the forecast period. Uveitis is a condition that causes inflammation in the uvea, which is the middle layer of the eye. The uvea contains many blood vessels that supply the retina, and inflammation can affect the function of the retina and cause vision problems. Uveitis can be caused by infections, autoimmune disorders, or other factors, and it can affect people of all ages.

Uveitis treatment aims to reduce inflammation, relieve symptoms, and prevent complications such as vision loss. The treatment approach depends on the underlying cause and severity of the uveitis. Common treatments for uveitis include:

Corticosteroids: These are anti-inflammatory medications that can be given orally, topically, or as injections into the eye.

Immunomodulatory drugs: These medications help to regulate the immune system and can be used in cases where uveitis is caused by an autoimmune disorder.

Antibiotics or antiviral medications: These are used to treat uveitis caused by an infection.

Biologic therapies: These are newer treatments that target specific components of the immune system and can be used in cases where other treatments have not been effective.

Surgery: In some cases, surgery may be needed to treat complications of uveitis, such as cataracts or glaucoma.

Effective treatment of uveitis requires close collaboration between an ophthalmologist and other healthcare providers, such as a rheumatologist or infectious disease specialist.

The global uveitis treatment market is expected to experience significant growth in the coming years, driven by factors such as an increasing incidence of uveitis, the introduction of novel treatment options, and rising awareness about the condition among healthcare providers and patients.

Corticosteroids continue to be the most commonly prescribed medication for uveitis treatment, followed by immunomodulatory drugs and biologic therapies. However, the market for biologic therapies is expected to grow at a faster rate, owing to their high efficacy and increasing adoption among healthcare providers.

The hospital pharmacy segment is expected to dominate the distribution channel market for uveitis treatment, owing to the high volume of uveitis patients seeking treatment in hospitals. However, the retail pharmacy and online pharmacy segments are expected to grow at a significant rate, owing to the increasing availability of uveitis medications through these channels.

Geographically, North America is expected to hold the largest market share, owing to factors such as a high incidence of uveitis, favorable healthcare infrastructure, and the presence of key market players in the region. However, the Asia-Pacific region is expected to grow at the fastest rate, owing to factors such as increasing healthcare expenditure, a large population base, and a growing awareness of uveitis among patients and healthcare providers.

Report Scope

Report Attributes

Description

Market Size in 2022

USD 705.6 Million

Market Forecast in 2031

USD 1,297.3 Million

CAGR % 2023-2031

4.6%

Base Year

2022

Historic Data

2019-2021

Forecast Period

2023-2031

Report USP

Production, Consumption, company share, company heatmap, company production capacity, growth factors and more

Segments Covered

By Treatment Type (Corticosteroids, Immunosuppressant, Monoclonal Antibodies, Cycloplegic Agents, Antibiotics, Antiviral, Antifungal, Analgesics), By Disease Type (Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis, Panuveitis), By Cause (Infectious and Non-infectious), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Regional Scope

North America, Europe, APAC, South America and Middle East and Africa

Country Scope

U.S.; Canada; U.K.; Germany; France; Italy; Spain; Benelux; Nordic Countries; Russia; China; India; Japan; South Korea; Australia; Indonesia; Thailand; Mexico; Brazil; Argentina; Saudi Arabia; UAE; Egypt; South Africa; Nigeria

Key Companies

Allergan; Inc.; Bausch & Lomb Incorporated; Santen Pharmaceutical Co.; Ltd; AbbVie Inc.; Novartis AG; Eyegate Pharmaceuticals; Inc.; Regeneron Pharmaceuticals; Eyepoint pharmaceuticals Inc.; and Alimera Sciences; Inc.

 

Impact of COVID

The COVID-19 pandemic has had a significant impact on the uveitis treatment market. The healthcare industry has been significantly impacted by the pandemic, with healthcare resources and personnel being diverted towards managing COVID-19 patients.

The pandemic has also led to disruptions in the supply chain of uveitis medications, leading to shortages and delays in treatment. Additionally, the closure of healthcare facilities and clinics has resulted in reduced patient visits, leading to a decline in uveitis diagnosis and treatment.

However, as the healthcare industry adjusts to the new normal, the uveitis treatment market is expected to recover. The increasing availability of telemedicine services and the adoption of digital health technologies are expected to drive the growth of the online pharmacy segment.

Furthermore, the introduction of new treatment options and the increasing focus on research and development by key market players are expected to drive the growth of the uveitis treatment market. The market is expected to rebound and continue its growth trajectory in the coming years.

Treatment Type Insights

Corticosteroids: Corticosteroids hold the largest market share among all the treatment types due to their effectiveness in reducing inflammation in uveitis patients. They are widely used in the treatment of uveitis and are available in different forms such as eye drops, injections, and pills.

Immunosuppressants: Immunosuppressants are the second-largest market segment due to their ability to suppress the immune system and reduce inflammation in uveitis patients. Drugs such as methotrexate, azathioprine, and mycophenolate mofetil fall under this category.

Monoclonal Antibodies: Monoclonal antibodies are becoming increasingly popular for the treatment of uveitis, as they target specific molecules that contribute to the inflammation. The use of monoclonal antibodies such as infliximab and adalimumab has shown promising results in treating uveitis patients.

Cycloplegic Agents: Cycloplegic agents are used to dilate the pupil and relieve pain in patients with uveitis. They are also used to prevent the formation of synechiae, which are adhesions between the iris and the lens.

Antibiotics: Antibiotics are used in the treatment of infectious uveitis caused by bacteria. They can be administered topically, orally, or intravenously depending on the severity of the infection.

Antivirals: Antivirals are used to treat viral uveitis caused by viruses such as herpes simplex virus and varicella-zoster virus. They are available in different forms such as eye drops, ointments, and pills.

Antifungal: Antifungal medications are used to treat fungal uveitis caused by fungi such as Candida and Aspergillus. They are available in different forms such as eye drops, ointments, and pills.

Analgesics: Analgesics are used to relieve pain in uveitis patients. They are available in different forms such as pills, injections, and topical ointments. However, their use is limited to short-term pain relief, and they are not a long-term treatment option for uveitis.

Disease Type Insights

Uveitis is an inflammation of the uvea, which is the middle layer of the eye. The treatment approach for uveitis varies based on the type and severity of the disease. The market for uveitis treatment is segmented based on disease type, which includes anterior uveitis, posterior uveitis, intermediate uveitis, and panuveitis.

Anterior uveitis is the most common type of uveitis and occurs in the front part of the eye. Posterior uveitis affects the back of the eye, including the retina and choroid. Intermediate uveitis affects the middle of the eye, including the vitreous and retina. Panuveitis affects all layers of the uvea.

The market for uveitis treatment is expected to grow due to the increasing prevalence of uveitis, advancements in treatment options, and rising healthcare expenditure. The demand for uveitis treatment is expected to increase due to the aging population and the rising prevalence of autoimmune disorders, which are risk factors for uveitis.

The corticosteroids segment is expected to hold the largest market share in the uveitis treatment market due to their effectiveness in reducing inflammation and improving visual outcomes. Immunosuppressants and monoclonal antibodies are also expected to witness significant growth due to their increasing use in the treatment of uveitis.

Cause Insights

Infectious Uveitis: Infectious uveitis is caused by various types of pathogens, including viruses, bacteria, fungi, and parasites. This segment is expected to hold a significant share of the uveitis treatment market due to the increasing prevalence of infectious uveitis globally.

Non-infectious Uveitis: Non-infectious uveitis refers to inflammation of the uvea caused by autoimmune disorders, inflammatory diseases, and other non-infectious causes. This segment is expected to hold a significant share of the uveitis treatment market due to the increasing incidence of autoimmune disorders and inflammatory diseases globally.

Regional Insights

North America dominated the uveitis treatment market with a significant share owing to the presence of major market players, increasing prevalence of uveitis, and a rising number of research activities for the development of new treatment options. The United States held the largest share in the North American region.

Europe held the second-largest share in the uveitis treatment market. The increasing prevalence of uveitis in the region, along with rising healthcare expenditure, is driving market growth in the region. The United Kingdom and Germany are the major contributors to the market growth in the region.

The Asia Pacific region is expected to witness the highest growth rate during the forecast period due to the increasing prevalence of uveitis, growing healthcare expenditure, and rising awareness about eye health among people. China, India, and Japan are the major contributors to the market growth in the region.

The Middle East and Africa and Latin America regions are also expected to witness significant growth in the uveitis treatment market due to increasing healthcare expenditure and rising awareness about eye diseases. However, the market growth in these regions may be limited due to the lack of skilled healthcare professionals and a low awareness level among people.

Competitive Analysis

Some of the major companies operating within the market are Allergan; Inc.; Bausch & Lomb Incorporated; Santen Pharmaceutical Co.; Ltd; AbbVie Inc.; Novartis AG; Eyegate Pharmaceuticals; Inc.; Regeneron Pharmaceuticals; Eyepoint pharmaceuticals Inc.; and Alimera Sciences; Inc. These players are focusing on product innovation, expansion, and partnerships to strengthen their market position and meet the growing demand for Uveitis Treatment globally.

Why to buy this Report?

The report provides quantitative and qualitative aspect for the market in terms of value and volume, along with supporting market trends, challenges, restraints.

The report provides an in depth analysis from both production and consumption point of view at the regional and country level. Key Factors considered within the report scope are Production capacity by countries/regions, average price, consumption ratio, revenue earned and gross margin.

The report provides competitive analysis of around 30-50 companies operated in the market, these companies are bifurcated into niche players, the leaders and major contenders. The companies are analyzed in terms of following factors such as:

§  Business Model

§  Production Capacity, Revenue, Sales, Gross Margin

§  Key Business Strategy

§  SWOT Analysis

In terms of competitive landscape, the report provides distinctive factors that would help the end user in taking a key decision within the business:

§  Company Share Analysis from 2018-2022

§  Company Analysis by Revenue and Sales

§  Company Production Capacity, Gross Margin

§  Company Share Analysis by Application/End Use

§  Company Share Analysis by Product/Specification

Frequently Asked Questions

·         What is the market size and growth projections?

·         What is the market size and growth projection for each of the market segments and sub-segments across Countries & Regions?

·         What are the top performing segments, and countries / regions of each of the markets?

·         What is the market size and growth rate across key countries / regions?

·         How big is the global & regional market in terms of revenue and volume?

·         How far market will grow in forecast period in terms of revenue and volume?

·         What factors will influence demand and supply trends across each markets during the forecast period?

·         What are the technology trends shaping various markets?

·         Which country / region has more opportunities?

·         What is the COVID-19 impact on the market and how long will it take to recover?

·         Who are the key competitors of market Players?

·         What are the market share (%) of Key Players?

·         What are the Merger & Acquisition, New Product Launch, Recent Development within each of the Markets?

·         What are PEST analysis, Ecosystem Analysis, Porter's Five Forecast Analysis, Ansoff Matrix, and SWOT Analysis among other analyses for diverse markets?

 

 

 


Quality Assurance Process

  1. We Market Research’s Quality Assurance program strives to deliver superior value to our clients.

We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.

Market Research Process




We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.

To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
  • Project kickoff meeting with client
  • Conduct frequent client communications
  • Form project steering committee
  • Assign a senior SR executive as QA Executive
  • Conduct internal editorial & quality reviews of project deliverables
  • Certify project staff in SR methodologies & standards
  • Monitor client satisfaction
  • Monitor realized value post-project

Case Study- Automotive Sector

One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached We Market Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).

Solution

The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research

The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.

Market Estimates and Forecast

In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.

Case Study- ICT Sector

Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.


Business Solution

An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.


Conclusion

The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2033.


CHOOSE LICENSE TYPE
QLOUD
Pricing

Select a license type that suits your business needs

Single User Access

US $4750

Only Four Thousand Seven Hundred Fifty US dollar

  • 1 User access
  • 15% Additional Free Customization
  • Free Unlimited post-sale support
  • 100% Service Guarantee until achievement of ROI
Multi User Cost

US $5750

Only Five Thousand Seven Hundred Fifty US dollar

  • 5 Users access
  • 25% Additional Free Customization
  • Access Report summaries for Free
  • Guaranteed service
  • Dedicated Account Manager
  • Discount of 20% on next purchase
  • Get personalized market brief from Lead Author
  • Printing of Report permitted
  • Discount of 20% on next purchase
  • 100% Service Guarantee until achievement of ROI
Enterprise User Cost

US $7750

Only Seven Thousand Seven Hundred Fifty US dollar

  • Unlimited User Access
  • 30% Additional Free Customization
  • Exclusive Previews to latest or upcoming reports
  • Discount of 30% on next purchase
  • 100% Service Guarantee until achievement of ROI